1. Febril nötropeni atağının başlangıcında ve ateşsiz 72,saatte alınan enfeksiyon belirteçlerinin karşılatırmasında ateşssiz 72.saatte alnan kan düzeyleri istatiksel olarak anlamlı düşük bulundu.
2. Febril nötropeni ataklarının 22’si mikrobiyolojik olarak tanımlandı.
3. Hastalar klinik ve mikrobiyolojik olarak tanımlanmış ve NBA olarak 2 grupta incelendiğinde duyarlılığı en yüksek belirteç prokalsitonin, en özgül belirteçler ise IL-6 ve IL-10’du.
4. Febril nötropeni ataklarında kültürde üreme olan olguları belirlemede en duyarlı belirteç IL-10, en özgül belirteçler ise IL-6 ve IL-8 olarak belirlendi.
5. Kan kültüründe üreme olan ve enfeksiyon odağı belli olan grubu belirlemede IL-6’nın ROC analizinde EAA’nı diğer belirteçlere göre daha yüksek bulundu.
Sonuç olarak, pediatrik kanser hastalarında enfeksiyon odağı olan olguları ve kan kültüründe üreme saptanan olguları belirlemek, klinik bulguların nötropenik hastalarda daha belirsiz olması nedeniyle tedaviyi planlamak için önemlidir. Febril nötropeni tanı ve izlemi açısından daha duyarlı ve özgül belirteçler saptamak için yaptığımız çalışmamızda kültürde üreme olan ve enfeksiyon odağı bulunan hastaları belirlemede IL-6, IL-8 ve IL-10 CRP’ye göre daha duyarlı ve daha özgül bulunmuştur.
8. KAYNAKLAR
1. Palazzi DL. The use of antimicrobial agents in children with fever during chemotherapy- induced neutropenia: the importance of risk stratification. Pediatr Infect Dis J. 2011;30(10):887-90.
2. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):56-93.
3. Koh AY, Pizzo PA. Infectious complications in pediatric cancer patients. In:Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams & Wilkins, Philadelphia 2011. p.1190.
4. Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45(10):1296-304.
5. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64 (2): 328-40.
6. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72(1) : 101-11.
7. Sarıbeyoğlu Tuğrul E, Akçay A. [Febrile Neutropenia in Pediatric Hematology and Oncology: Descriptions and Management]. Turkiye Klinikleri J Pediatr Sci 2009;5(1):120-30.
8. Kebudi R.[Diagnosis and Treatment of Febrile Neutropenia in Children & Studies Conducted in Turkey]. Turkiye Klinikleri J Pediatr Sci 2009;5(4):145-56
9. Badiei Z, Khalesi M, Alami MH, Kianifar HR, Banihashem A, Farhangi H, et al. Risk factors associated with life-threatening infections in children with febrile neutropenia: a data mining approach. J Pediatr Hematol Oncol. 2011;33(1):9-12.
10.Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol. 2008;25(5):385-92.
11.Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(1):51-9.
12.El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer. 2011;57(2): 283-8.
13.Santolaya ME, Farfán MJ, De La Maza V, Cociña M, Santelices F, Alvarez AM, et al. Diagnosis of bacteremia in febrile neutropenic episodes in children with cancer: microbiologic and molecular approach. Pediatr Infect Dis J. 2011;30(11): 957-61.
14.Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2009;31(9): 623–9.
15.Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am. 2009;27(3): 525–44.
16.Santolaya ME, Alvarez AM, Aviles CL, Becker A, King A, et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia and fever. Pediatr Infect Dis. 2008; 27(6): 538–43.
17.Pizzo PA, Walsh TJ. Fungal infections in the pediatric cancer patient. Semin Oncol. 1990;17(6):6-9.
18.Fisher BT, Alexander S, Dvorak CC, Zaoutis TE, Zerr DM, Sung L. Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. Pediatr Blood Cancer. 2012;59(1):11-5.
19.Torres JP, Labraña Y, Ibañez C, Kasaneva P, Farfán MJ, De la Maza V, Villarroel M, Vergara I, Piemonte P, Zubieta M, Salgado C, Tordecilla J, Topelberg S, O Ryan M, Santolaya ME. Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia. Pediatr Infect Dis J. 2012;31(9):889-93.
20.Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, Hakim H, Santolaya M, Castagnola E, Davis BL, Dupuis LL, Gibson F, Groll AH, Gaur A, Gupta A, Kebudi R, Petrilli S, Steinbach WJ, Villarroel M, Zaoutis T, Sung L; International Pediatric Fever and Neutropenia Guideline Panel. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427-38.
21.Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15(1):139-47
22.Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19(1):253-9.
23.Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3):373-9
24.Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology. 1985;157(3):611-4.
25.Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41(5):654-9.
26.Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-Beta-D- glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46(6):878-85.
27.Castagnola E, Cesaro S, Dalle J, Engelhard D, Hope W, Lehrnbecher T et al. ECIL 4 – Pediatric Group Considerations for Fungal Diseases and Antifungal Treatment in Children. Presented at: 4th European Conference on Infections in Leukaemia,8-10 Sep 2011.
28.Castagnola E, Furfaro E, Caviglia I, Licciardello M, Faraci M, Fioredda F et al. Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation. Clin Microbiol Infect. 2010;16(8):1197-203.
29.Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417-27.
30.Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-59.
31.Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340(10):764-71.
32.Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391-402.
33.Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam- aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev. 2003;(3):CD003038.
34.Uygun V, Karasu GT, Ogunc D, Yesilipek A, Hazar V. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. Pediatr Blood Cancer. 2009;53(4):610
35.Simon A, Lehrnbecher T, Bode U, Groll AH, Tramsen L, Wieland R,et al. Piperacillin- tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis. 2007;26(11):801-6.
36.Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006;23(3):177-86.
37.Viscoli C, Cometta A, Kern WV, Bock R, Paesmans M, Crokaert F,et al. International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect. 2006;12(3):212-6.
38.Kılıçturgay K.(2003).Enflamasyonun akut faz cevabıyla izlenmesi. İmmunoloji, Nobel Tıp Kitabevi Yayınları, İstanbul, 226-7.
39.Mackowiak PA. Temperature Regulation and the Pathogenesis of Fever. In: Mandell GL, Bennet JE, Dolin R (eds). Principles and Practise of Infectious Disease. Sixth ed. Pennsylvania: Elseiver Churchill Livingstone Inc, 2005. pg. 703-15.
40.Durum SK, Openheim JJ. Proinflammatory cytokines and immünity. In: Paul WE Fundemental İmmünology. 3rd ed. New York Raven Press Ltd 1993; 801-35.
41.Bellanti JA, Kadlee JV, Escobar- Guotemez. Cytokines and the immün response. Pediatr Clin North Am, 1994; 41: 597-623.
42.Dinarello CA. IL-1 and TNF. In: Lachman PJ, Peters DK, Rosen FS, Walport MJ. Clinical Aspects of İmmunology. 5th ed. Boston: Blackwell Scientific Publication 1993; 1:267-313.
43. Lau AS. Cytokines in the patogenesis and treatment of infectious diseases. In: Aranoff SC, Hughes WT, Kohl S, Speck WT, Wald ER. Advances in Pediatric İnfectious Diseases. Chicago: Mosby Year Book 1994; 211-31.
44.Oppenheim JJ, Ruscetti FW, Faltynek C. Cytokines. In Sites DP, Terr AT. Basic and Clinical İmmunology. 7th ed. California: Appleton and Lange 1991; 78-101.
45.Balkwill FR, Burke F. The Cytokine Network. Immünology Today 1989; 10: 299-304.
46. Schindler R, Moncilla J. Correlation and interactions in the production of IL-6, IL-1 and TNF in human blood mononuclear cells. Blood 1990; 75: 40-7.
48.Felgin RD, Adcock LM, Miller DJ. Postnatal bacterial infections. In: Fanaroff AA, Martin RJ. Neonatal Perinatal Medicine 5th ed. Vol 2, Philadelphia Mosby Year Book 1992; 612-59.
49.Castell JV, Gomez MJ. IL-6 is a major regulator of the acute phase protein synthesis in human hepatocytes. FEBS LETT 1989; 237-42.
50.Fubuda Y, Ishida N. IL-6 down regulates the expression of transcripts encoding cytochrome P450 in human hepatoma cells. Biochem Res Common 1992; 184: 960.
51.Richards C, Gauldie J. Cytokine control of acute phase protein expression. John Libbey Euro Text. Paris 1991; 2950.
52.Mehr SS, Doyle LW, Rice GE, Vervaart P, Henschke P. Interleukin-6 and interleukin-8 in newborn bacterial infection. Am J Perinatol. 2001; 18: 313-24.
53.Dinarello CA, Wolf SM. The role of IL-1 in disease. N Engl J Med 1993; 328: 106-13.
54.Akira S, Kishimato T. IL-6 and TNF in acute phase response and viral infection. İmmunol Review 1992; 127: 25-50.
55.Howard MC, Miyajima A, Coffman R. T cell derived cytokines and their receptors. In: Fundemental İmmunology. 3rd ed. New York: Raven Press Ltd. 1993; 763-800.
56.La Pine TR, Hill HR. İmmunmodifiers applicable to the prevention and management of infectious diseases in children. In: Aranoff SC, Hughes WT, Kohl S, Spect WT, Wold ER. Advances in Pediatric İnfectious Diseases. Chicago: Mosby Year Book 1994; 36-43.
57.Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Ouaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin İmmünol. 2011;127(3):701-21.
58.Kishimato T. The biology of IL-6. Blood 1989; 74: 1-10.
59.Alam R. (2003) Chemokines in cell movement and infammation. Rosenwasser LJ, Borish L. Cytokines in allergic inflammation. Church MK, Shute JK, Sampson AP. Mast cell- derivated mediators. Hirota K, Adolphson CR, Gleich GC. Biology of eosinophils. In: Adkinson NF, Yunginger JW, Busse WW, Bachner BS, Holgate ST, Simons FER.
60.Hirano T, Akira S, Taga T, Kishimato T. Biological and clinical aspects of IL-6. İmmunol Today 1990; 11: 443-449.
61.Abbas AK, Lichtman AH. Effector mechanisms of İmmüne Responses. In Cellular and molecular İmmunology. 5th ed. USA: WB Saunders Company2005;11:244-74.
62.Chiesa C, Signore F, Assuma M, Buffone E, Tramontozzi P, Osborn J, Pacifico L. Serial measurements of C-reactive protein and ınterleukin-6 in the immediate postnatal period: referance intervals and analysis of maternal and perinatal confounders. Clinical Chemistry. 2001;47:1016-22.
63.Girardin EP, Berner ME. Serum TNF in newborns at risk for infections. J Pediatr 1990;149: 645-7.
64. Groll AH, Meiser A, Weise M. IL-6 is an early mediator in neonatal sepsis. The Pediatr Infect Dis J 1992; 11: 496-8.
65.Hack CE, De Groot ER, Felt- Bresma RJF, et al. Increased plasma levels of IL-6 in sepsis. Blood 1989; 74: 1704-10.
66.Rusconi F, Paraizzi F, Garlachi L, et al. IL-6 activity in infants and children with bacterial menengitis. Pediatr Infect Dis J 1991; 10: 117-21.
67.Sullivan JS, Kilpatrick L, Castarino AT Jr, Lee SC, Harris MC. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992; 120: 510-5.
68.Oppenheim JJ, Ruscetti FW. Cytokines. In: Stites DP, Terr AI, Parslow TG. Medical
İmmunology. 9th ed. USA: Appleton& Lange 1997;10:162-4.
69.David R, Machova Z, Beck-Sickinger AG. Semisynthesis and application of carboxyfluorcein-labelled biologically active human interleukin-8. Biol Chem. 2003;384:1619-30.
70.Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
71.Kim JM, Brannan CI, Copeland NG, Jenkins NA, Khan TA, Moore KW. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J
İmmünol 1992;148:3618-23. 204.
72.Cunha FQ, Moncada S, Liew FY. Interleukin-10 inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun, 1992;182:1155-9.
73.Niiro H, Otsuka T, Tanabe T, Hara S, Kuga S, Nemoto Y, Tanaka Y, Nakashima H, Kitajima S, Abe M. Inhibition by Interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: its underlying mechanism in comparison with interleukin-4. Blood, 1995;85:3736-45.
74.de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
75.de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
76.Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W, Cell. Interleukin-10-deficient mice develop chronic enterocolitis 1993;75:263-74.
77.Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J İmmünol 1995;154:4341-50.
78.Urbonas V, Eidukaitė A, Tamulienė I. Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patients. Cytokine. 2012 Mar;57(3):313-5.
79.Meidani M, Khorvash F, Abolghasemi H, Jamali B. Procalcitonin and quantitative C- reactive protein role in the early diagnosis of sepsis in patients with febrileneutropenia. South Asian J Cancer. 2013;2(4):216-9.
80.Kallio R, Surcel HM, Bloigu A, Syrjälä H. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer. 2000;36(7):889-94.
81.Urbonas V, Eidukaitė A, Tamulienė I. The predictive value of solublebiomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncologypatients with chemotherapy- induced febrile neutropenia. Cytokine. 2013;62(1):34-7.
82.Jekarl DW, Lee SY, Lee J, Park YJ, Kim Y, Park JH, Wee JH, Choi SP. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis. 2013 Apr;75(4):342-7.
83.Kitanovski L, Jazbec J, Hojker S, Gubina M, Derganc M. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis. 2006;25(6):413 5.
84.Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10:6.
85.Vänskä M, Koivula I, Jantunen E, Hämäläinen S, Purhonen AK, Pulkki K, Juutilainen A. IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients. Cytokine. 2012;60(3):787-92.
86.Lehrnbecher T, Venzon D, de Haas M, Chanock SJ, Kühl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29(2):414-9.
87.Diepold M, Noelke P, Duffner U, Kontny U, Berner R. Performance of IL-6 and IL-8 serum levels in pediatric oncology patients with neutropenia and fever for assessment of low-risk. BMC Infect Dis.2008;8:28.
9. ÖZET
PEDİATRİK YAŞ GRUBUNDA FEBRİL NÖTROPENİ TANI VE İZLEMİNDE IL-6,